In addition, we used P38 MAPK inhibitors targeting GCLM phosphorylation to assess their efficacy in sensitizing CRC tumors to the oxaliplatin-based clinical standards of care (FOLFOX regimen) in the PDX model. Here, GCLM is linked to colorectal carcinoma.